Using nanopore sequencing for faster breast cancer diagnosis in Tanzania
Nanopore Sequencing for Accelerating Breast Cancer Diagnosis in Tanzania: A Prospective Observational Study
This study is testing if a new method called nanopore sequencing can help doctors in Tanzania diagnose breast cancer faster and more accurately than the usual tests.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Bonn Academic / other |
| Locations | 1 site (Moshi) |
| Trial ID | NCT06633276 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the feasibility of nanopore sequencing as a diagnostic tool for breast cancer in Tanzania. It will compare the accuracy and turnaround time of nanopore sequencing against the current standard of care, which includes histopathology and biomarker analysis. By analyzing excess fresh tissue samples from patients with suspected breast cancer, the study seeks to demonstrate that nanopore sequencing can provide rapid and cost-effective results, potentially improving treatment planning in resource-limited settings.
Who should consider this trial
Good fit: Ideal candidates are patients with suspected breast cancer who are undergoing biopsy or surgical resection and can provide excess fresh tumor samples.
Not a fit: Patients who have already started therapy for breast cancer or are unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to quicker and more accurate breast cancer diagnoses, enhancing treatment outcomes for patients.
How similar studies have performed: While the use of nanopore sequencing in breast cancer diagnosis is a novel approach, similar studies in other contexts have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with suspected diagnosis of breast cancer undergoing biopsy or surgical resection after specialist consultation as per institutional guidelines * Excess fresh tumor sample * Written informed consent Exclusion Criteria: * Unable to provide informed consent * Patients who have already commenced therapy for BC (except for treatment other than biomedicine, e.g. herbal medicines)
Where this trial is running
Moshi
- Kilimanjaro Christian Medical Centre — Moshi, Tanzania (Recruiting)
Study contacts
- Principal investigator: Oliver Henke, MD — Section Global Health, University Hospital Bonn
- Study coordinator: Oliver Henke, MD
- Email: Oliver.Henke@ukbonn.de
- Phone: +49 (0) 228 287 51521
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.